Figure 1
From: Metabolomic studies in tissues of mice treated with amifostine and exposed to gamma-radiation
(A) Experimental and analytical design of the study. Bone marrow, jejunum and lung samples were collected from irradiated and/or amifostine treated mice at day 4 or 9 and processed for untargeted LC-MS profiling. Metabolomics pathway and network analysis were analyzed by Mummichog v2.0. Putative annotation was performed by an in-house CEU Mass Mediator RESTful API service, which search Kegg, HMDB, LipidMaps, Metlin,and PubChem and is consumed in the R package “cmmr”. Validation with tandem mass spectrometry was performed by the TandemQuery tool (Li et al., unpublished) and the NIST 2017 MS/MS spectra database. (B) Radioprotective efficacy of different doses of amifostine administration in irradiated CD2F1 male mice. Mice were administered vehicle or amifostine (50 or 200 mg/kg) 30 min prior to irradiation (60Co γ-radiation, 9.6 Gy, 0.6 Gy/min). Survival was monitored for 30 days post irradiation.
